First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

Inclusion Criteria:

1. Provision of written informed consent

2. HLA-A*02:01 positive

3. MAGE-A4 positive tumor

4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) [ECOG PS] 0 or 1

5. Selected advanced solid tumors

6. Relapsed from, refractory to, or intolerant of standard therapy

7. Measurable disease per RECIST v1.1

8. Adequate organ function

9. If applicable, must agree to use highly effective contraception

Exclusion Criteria:

1. Symptomatic or untreated central nervous system metastasis

2. Inadequate washout from prior anticancer therapy

3. Significant ongoing toxicity from prior anticancer treatment

4. Recent surgery

5. Clinically significant cardiac disease

6. Active infection requiring systemic antibiotic treatment

7. Human immunodeficiency virus (HIV) at risk of acquired immunodeficiency syndrome (AIDS)-related outcomes

8. Active hepatitis B virus (HBV) or hepatitis C virus (HBC)

9. Ongoing treatment with systemic steroids or other immunosuppressive therapies

10. Significant secondary malignancy

11. History of chronic or recurrent active autoimmune disease requiring treatment

12. Uncontrolled intercurrent illness

13. Pregnancy or lactation.